Dr Md Arif Sheikh

BSc, PhD.

RESEARCH INTERESTS

Anti-ageing:

My long-term research interest revolves around combating the process of aging, with a specific focus on the thymus gland, an essential element in our immune system. The thymus, located behind the breastbone, is instrumental in generating T cells that are crucial for fighting infections. However, as we age, the thymus undergoes involution, shrinking in size and diminishing its ability to produce T cells. This natural but unfavorable process not only accelerates aging but also makes the body more susceptible to various health issues including infections, cancers, and autoimmune diseases.

We are focused on breakthroughs that could reverse or slow thymic decline, enhancing immunity and slowing aging. T-BOOSTER is a key innovation by T-Booster Limited, UK—a supplement with 18 natural ingredients aimed at thymic regeneration and T cell production, promising to boost immunity, improving overall health and longevity.

We are pleased to announce that Avix Pharmaceuticals Limited has been granted permission to conduct a clinical trial at Bangabandhu Sheikh Mujib Medical University (BSMMU) in Bangladesh, aiming to assess the efficacy of T- Booster on thymus functionality in 400 volunteers.

Green antibiotic:

By 2050, antimicrobial resistance (AMR) is anticipated to cause 10 million human fatalities annually, exceeding the death rate from cancer. This crisis is exacerbated by the prevalent use of antibiotics in animal agriculture, which accounts for up to 80% of antibiotic use in the US, emphasizing the intertwined nature of human and animal health. The rise in AMR highlights the critical need for sustainable antibiotic practices to avert catastrophic health, environmental, and economic consequences.

In response, Avix is championing green antibiotics, a groundbreaking initiative for a plant-based alternative in animal agriculture, supported by proof-of-concept studies. These green antibiotics aim to:

1. Offer a safe, natural, and effective substitute to traditional antibiotics.

2. Counteract the development of antibiotic-resistant bacteria at its source.

3. Maintain the economic viability of the aquaculture and poultry sectors, with market values of $200 billion and $350 billion, respectively, by providing a sustainable antimicrobial option.

4. Encourage a comprehensive strategy that considers the well-being of both animals and humans.

5. Preserve the effectiveness of antibiotics for future generations.

Our research introduces green antibiotics as an innovative response to superbugs, aiming for sustainable animal agriculture.